Overview

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To determine the most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas.
Phase:
Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborator:
Pharmacia and Upjohn
Treatments:
Irinotecan
Mitomycin
Mitomycins